Phytonadione (Phytonadione (Vit K1)) Patent Expiration, LOE Window & CMS Spending
Phytonadione (Phytonadione (Vit K1)) by Zydus Pharmaceu: Off-Patent Genericized (AB Competition), 0 AB generics, $5.9M 2024 CMS Part D & Medicaid spend, and $1,069 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Zydus Pharmaceu |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.9M |
| 2024 Medicare Part D Spend | $26K |
| 2024 Medicaid Spend | $5.8M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,069 intro WAC) |